BIO Early-Stage Resources Hub
Access a range of exclusive resources, including cost-saving programs, educational webinars and stay up-to-date with the latest BIO Emerging Companies Section (ECS) events with our comprehensive resource center, designed to empower early-stage companies and help them thrive.
BIO members can access additional content by clicking here and entering a password. If you’re a BIO member and need to access the page, please email bioemergingcompanies@bio.org.
BIO is focused on advancing tax policy that recognizes early-stage biotech companies as fundamental to the long-term economic growth of the United States. An overview of BIO’s tax policy priorities are below.
BIO letter to House Small Business Committee outlining 7 tax policy recommendations for supporting biotechs.
BIO and BIO members urge immediate legislative action to repeal the harmful R&D amortization provision that went into effect in 2022.
BIO, BIO members, and State affiliates urge immediate legislative action to repeal the harmful R&D amortization provision that went into effect in 2022.
An overview of BIO’s tax policy priorities.
Talking points on the background, impact on the biotechnology community and solution.
The SBIR program plays an important role in financing promising early-stage innovation. Here are some resources to help you draft applications and track critical submission deadlines.
A three-month schedule for completing an SBIR/STTR grant application including key activities to complete.
A PowerPoint presentation on the grant application process. An overview of how to identify opportunities, how to compose a proposal, and project management tips.
A white paper on regulatory grant writing, best practices for developing proposals, success factors, and tackling grant writing challenges.
A grant application flowchart from start to finish. Includes decision points and scenarios to help determine which agencies and grants to apply to.
Partnerships between small biotechs and large pharma companies can drive scientific advancements and expedite drug development. Our goal is to provide the tools needed to facilitate these collaborations.
This resource provides guidance to assist early-stage companies in identifying potential large biopharma partners.
BIO’s comments on legislative and regulatory tax issues, securities law issues, accounting, and other capital formation policy initiatives.
Comments on proposed rule to require information about a registrant’s climate-related risks that are reasonably likely to have a material impact on its business, results of operations, or financial condition.
Comments on proposed rule to enhance and standardize disclosures regarding cybersecurity risk management, strategy, governance, and incident reporting by public companies.
Comments on proposed rule to amend regulations governing the national market system (NMS).
Comments on proposed rule to require money managers to disclose within 14 calendar days after month-end certain gross short positions on companies.
Comments on proposed rule to adapt a variable minimum pricing increments for the quoting and trading of NMS stocks, reduce access fee caps, and enhance transparency of better priced orders.
Comments on SEC request for information on climate risk disclosures.
Comments on proposed rule governing proxy voting advice.
Comments in response to Federal Trade Commission’s Pharmaceutical Task Force’s request for public comment.
Comments to FTC on merger enforcement.
Comments in response to FTC Solicitation for Public Comments on the Business Practices of PBMs and Their Impact on Independent Pharmacies and Consumers.
Statement for the Record to House Financial Services Committee, Subcommittee on Capital Markets.
Testimony of BIO’s Chief Policy Officer before the Senate Subcommittee on Competition Policy, Antitrust, and Consumer Rights on consolidation and monopoly power.
BIO Support of H.R. 4618, to amend short sale reporting requirements.
An overview of CFIUS and how the Administration’s focus on protecting the U.S. Biotech Industry could cause unintentional harm by impeding foreign investment and collaborations.
BIO Letter to Senate Banking Committee in support of proposals to foster capital formation for biotechs.
See below for a collection of recent reports from BIO’s Industry Analysis team. To view the full collection of reports, visit bio.org/ia-reports. To view BIO data on emerging therapeutic company investment and deal trends. click here. To view BIO data on FDA Approval Trends and clinical development pipeline, click here.
New BIO Industry Analysis trend data have been released for Emerging Therapeutic Company Investment, R&D-Stage Out-licensing, and Acquisitions.
New research released by Vital Transformation (VT) shows that the Inflation Reduction Act (IRA) will stifle the ability of companies to continue research and development across a broad range of therapeutic areas.
BIO’s Industry Analysis Team presents FDA Approval Trends that are filterable by various attributes including: size of company, molecule size, disease area, and various expedited approval pathways.
This report investigates recent investment into antibacterial innovation and the current clinical pipeline that will help bridge the gaps in the antibacterial armamentarium.
This report focuses on vaccine innovation and success at the clinical stage, as well as the innovation of prophylactic antibodies in clinical trials.
BIO Office Hours allow you to schedule one-on-one meetings with subject matter experts. Below are materials from past office hours. For more information, visit bio.org/save/office-hours.
Contains graphs and charts on cyber threat trends. View data on assets affected, annual claims, and more by industry and revenue size.
